cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Passive Mobilization in Patients With Subacromial Syndrome

From a biomechanical point of view, subacromial syndrome causes an increment in the anterior and superior translation of the humeral head, which increases compression in the adjacent tissues of the subacromial space, aggravating the symptoms of the patients. Conservative treatments are the first option for subacromial syndrome management, despite the fact that there is limited evidence about its effectiveness, due to the lack of experimental studies.

The aim of this study is to evaluate the effectiveness of a passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint, within a multimodal approach to reduce pain and improve the range of motion in patients with subacromial syndrome.

Subacromial syndrome, also known as subacromial impingement, is the most frequent disorder in the shoulder joint. It has a multifactorial origin and represents a wide spectrum of pathologies. Its main consequences are pain and loss of function in the glenohumeral joint. From a biomechanical point of view, subacromial syndrome causes an increment in the anterior and superior translation of the humeral head, which increases compression in the adjacent tissues of the subacromial space, aggravating the symptoms of the patients. Conservative treatments are the first option for subacromial syndrome management, despite the fact that there is limited evidence about its effectiveness, due to the lack of experimental studies.

The aim of this study is to evaluate the effectiveness of a passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint, within a multimodal approach to reduce pain and improve the range of motion in patients with subacromial syndrome. To this end, a randomized clinical trial will be carried out in the Montpellier Clinic in Zaragoza. Twenty-two patients will be recruited and randomly assigned to one of the two groups (intervention and control). Both groups will receive a standardized treatment consisting of: 10 sessions of infrared rays, and a program of therapeutic exercises and indications to improve their postural hygiene. In addition, the intervention group will receive a passive joint mobilization in the glenohumeral joint of 5 minutes. Pain intensity, range of motion and functionality of the glenohumeral joint will be measured in the first session before any treatment and in the tenth session after the treatment.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of subacromial syndrome
* Pain at rest, which increases when doing active movements
* Neer´s impingement test positive
* Hawkins Kennedy test positive
* Pain lasting more than one month
* Anteriorization of humeral head
* Full capacity (physical and cognitive) to participate in the study and give consent.

Exclusion Criteria:

* Infiltrations during the previous six months
* Traumatic origin of pain
* Complete tear of any rotator cuff tendon
* Bilateral pain
* Previous surgical intervention in the affected shoulder
* Patients planning to start with other treatments during the clinical trial.
Outcome of Embryo Culture at Two Oxygen Tensions

The purpose of this study is to assess whether reduced oxygen tension in embryo culture has any effect on clinical outcome.


Eligibility Criteria:
Inclusion Criteria:

* stimulated Intra Cytoplasmic Sperm Injection (ICSI) cycle

Exclusion Criteria:

* less than one mature (metaphase II) oocyte at the time of denudation
Gingival Crevicular IL-34 and CSF-1 Levels in Patients With Periodontitis and Uncontrolled Type 2 Diabetes

Type 2 diabetes mellitus is a metabolic disorder. There is a bidirectional association between periodontal disease and DM. Currently there is no data relationship between CSF-1 and IL-34, periodontal disease and diabetes.The aim of this study to investigate GCF levels of IL-34 and CSF-1 in periodontitis subjects with diabetes.

Periodontally healthy (H), periodontitis, and periodontitis with diabetes patients, were recruited for this study.

1. Inclusion criteria for H groups: Individuals with clinically healthy gingiva, no attachment and bone loss, and less than 10% bleeding on probing were included.
2. Inclusion criteria for periodontitis groups: Systemically healthy individuals with interdental CAL ≥ 5 mm and PPD ≥ 6 mm were included.
3. Inclusion criteria for periodontitis with diabetes groups: Type 2 diabetes patients with interdental CAL ≥ 5 mm, PPD ≥ 6 mm, and HbA1c ≥ 6.5% were included.

The plaque index (PI), gingival index (GI), presence of bleeding on probing (BOP), PD, and clinical AL were used for clinical periodontal assessments. All assessments were done with a manual probe. GCF samples were obtained and analyzed using an enzyme-linked immunosorbent assay.

Eligibility Criteria:
Inclusion Criteria:

* have 20 teeth
* have diabetes .

Exclusion Criteria:

* Individuals have systemic disease
* smokers;
* pregnant
* those using drugs;
Phenotyping Diabetic Retinopathy

The purpose of this study is to validate and characterize phenotypes of diabetic retinopathy (DR) progression based on available clinical data (demographic, systemic and ophthalmic data).

This study aims to validate and characterize phenotypes of diabetic retinopathy (DR) progression using ophthalmic and systemic data from type-2 diabetic subjects followed at the AIBILI Clinical Trial Center in the last 10 years.

Macular Edema (ME) development during the study period, mainly Clinically Significant ME (CSME) needing treatment, will be the primary indicator for DR progression. CSME will be considered as the primary end-point and will be used to identify phenotypes (and risk markers) of DR progression.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of DR.
* Females or Males;
* Age over 18 years;
* Signed Informed Consent;
* Previous follow-up with regular systemic and ophthalmic assessments.

Exclusion Criteria:

* Cataract or other eye disease that may interfere with fundus examinations;
* Vitreous syneresis or posterior vitreous detachment;
* Dilatation of the pupil \< 5 mm.
SuperSTAT Noninvasive Blood Pressure Monitor Evaluation

The accuracy and/or performance of the GE DINAMAP noninvasive blood pressure (NIBP) monitors may be improved with modifications in software and/or hardware monitoring techniques and/or accessories. When changes are being made to the GE Monitor, testing can be done to evaluate performance of the investigational devices during and/or after product development.


Eligibility Criteria:
Inclusion criteria

* Signed informed consent
* Ability to single or dual monitor NIBP, ECG, and/or SpO2, whether or not already being monitored for any or all of these parameters.

Exclusion Criteria

* Any subject deemed too unstable, at the clinician's discretion, to participate in the study
* Any subject with a cardiac anomaly that would cause a disparity between aortic pressures and the periphery.
* Any subject who cannot tolerate, in the opinion of the clinician, multiple blood pressure measurements
* Known disease state or medical condition that A) compromises circulation to the extremity (ies), B) compromises musculo-skeletal integrity, or C) otherwise contraindicates use of a NIBP cuff and/or SpO2 sensor on an extremity or ECG patches on skin
* Excessive movement or excitability causing false values or no determinations (SP10 accuracy study only)
Computer Aided Diagnosis of Colorectal Polyps

The purpose of this study is to assess whether computer aided technology (CAD) can help in the diagnosis of polyps found the bowel compared with visual inspection alone and therefore whether it is beneficial in helping clinicians to decide whether to remove a polyp or not. Presently, most endoscopists remove all polyps found and send them to the laboratory for testing. The number of colonoscopies is increasing, meaning that more polyps are detected and removed. This comes at a significant cost to the health service and increases the time taken to complete a colonoscopy.

Removing precancerous polyps from the bowel during a colonoscopy (camera test) is the cornerstone of colorectal cancer screening and prevents polyps developing into bowel cancer. Most polyps develop in the rectosigmoid colon (lower part of the bowel). Many polyps never grow into cancer and it can be difficult for the clinicians performing the procedure (endoscopists) to tell which ones are precancerous. This means many polyps are removed unnecessarily, with a considerable waste of resources.

A recent preliminary study indicates a novel artificial intelligence system (EndoBRAIN) for computer-aided diagnosis may be able to distinguish different types of polyps during colonoscopy and therefore help doctors decide which polyps to remove. This study aims to compare the in accuracy of artificial intelligence against the endoscopist's assessment for diagnosis of diminutive (\<5mm) polyps in the lower colon.

Patients who are age 18 years or older who undergo colonoscopy for any indication at the participating clinical centres and are diagnosed with diminutive rectosigmoid polyps are eligible for study enrolment. For each detected polyp in the rectosigmoid colon, endoscopists will assess the polyp type using standard colonoscopies (cameras) and then with the use of the EndoBRAIN technology.

The polyps will be removed and sent to the laboratory for testing. The difference between clinician diagnosis and EndoBRAIN diagnosis will be compared with the laboratory findings. We hypothesize that the EndoBRAIN technology provides a superior accuracy in identifying precancerous rectosigmoid polyps, compared to endoscopist's own prediction with a standard colonoscope.

If the trial confirms the superior accuracy of the EndoBRAIN system, polyps classified as non-cancerous with the EndoBRAIN system no longer need to be removed, meaning a large gain for patients and society, due to significantly less polypectomies and pathology reviews.

Eligibility Criteria:
Inclusion Criteria:

* Individuals 18 years or older who are scheduled for screening, surveillance, diagnostic, or therapeutic colonoscopy at at King's College Hospital with diminutive rectosigmoid polyps.

Exclusion Criteria:

* Diminutive polyps with known histology
* Inflammatory bowel disease
* Polyposis syndrome (e.g., familial adenomatous polyposis, serrated polyposis)
* History of chemotherapy or radiation therapy for colorectal lesions
* Inability to undergo polypectomy (e.g. intake of anticoagulants, comorbidities, or patient refusal)
* Pregnancy
The FibreGum Study - Changing the Course of Obesity in Children

The aim of this study is thus to assess the effect of a chewing gum containing fibres on body weight, metabolism and the oral and intestinal microbiomes in a population of obese children.


Eligibility Criteria:
Inclusion Criteria:

* Informed Consent according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (ICH/GCP) regulations prior to any study specific procedures
* Obesity as determined by a BMI ≥97th percentile using the Swiss paediatric, age- and sex-matched growth charts
* Newly referred within the last month to a tertiary weight management clinic
* Participant willing to use the study specific monitoring app on his/her own or legal representatives' smartphone

Exclusion Criteria:

* Antibiotic administration in the last 6 months
* Pre- or probiotic treatment in the last 6 weeks
* Any professionally supervised treatment for weight management within the last year
* Consumption of more than one nicotine product per month (e.g. cigarette, gum)
* Adolescent females: any stages of known pregnancy or lactation period
* Congenital disorder affecting the cardiovascular, hepatic or respiratory system in a relevant way (as per PI's or specialist's evaluation)
* Malignant disease on treatment or previous tumour affecting the appetite system (e.g., suprasellar, hypothalamic tumours)
* Systemic antibiotic or anti-inflammatory medication (e.g. systemic intake of glucocorticoids) over the last 7 days
* Known eating disorder (medically diagnosed)
* Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation
* Dependency from the sponsor or the clinical investigator
* Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, etc. of the participant and/or legal representative
Virtual Reality (VR) for Prone Pain Procedures

The purpose of this study is to evaluate the effectiveness of virtual reality (VR) distraction in patients undergoing interventional pain procedures in the prone position. VR has been shown to improve patient experience during interventional pain procedures, however, many of these procedures are done in the prone position making VR a challenge. This study will evaluate the effect of a VR headset and support in patients undergoing prone interventional pain procedures compared to control.


Eligibility Criteria:
Inclusion Criteria:

* Patients aged 18 years old or older, who are referred to University of California Davis Pain Medicine Clinic and require an interventional pain procedure
* English speaking and with the ability to understand oral and written instructions

Exclusion Criteria:

* Pregnant women
* Prisoners
* Patients who have high risk of motion sickness, seizure disorder, or visual/hearing impairment
Progressive Muscle Relaxation and Adaptation to Old Age

Changes and limitations in the aging process affect adaptation to old age. It is important for women to adapt to the problems of old age, find a solution and cope. This study was aimed to determine the effect of progressive muscle relaxation exercises on the level of depression and adaptation to old women.

The aging process is considered as a result of the decline observed in basic cognitive functions such as attention, perception, memory, and causes problems in the communication of the elderly with the environment. For these problems, it affects the adaptation of the elderly in his environment and himself.

There are a limited number of studies in the literature to increase the adaptation of older individuals to old age. In the studies in the literature, it was stated that the rate of depression is higher in female individuals, and being male and having a high education level positively affect the adaptation of individuals to old age. In a national study, it was determined that as age increases, adaptation to old age decreases.

Progressive muscle relaxation (PMR), one of the nonpharmacological methods, involves the voluntary stretching and relaxation of large muscle groups (hand-starting, foot-end muscle groups) in the human body. It is known that PMR exercises are frequently used in nursing research because of the effects of reducing anxiety and fatigue and improving sleep quality, and reducing nausea-vomiting. However, no study was found on the effect of depression and adaptation to old age. Due to these positive effects of PMR determined in the literature, it is thought that elderly women can positively affect their levels of depression and adaptation to old age.

Objective: Evaluate the effects of progressive muscle relaxation on the depression and adaptation of elderly women to aging.

Methodology: This is randomized clinical test. The sample was made up of 49 elderly women who applying to the family health center (21 in the experimental group and 28 in control group). The progressive muscle relaxation was employed. In order to collect the data, we adopted the interview with form filling technique, using the introductory information form, Assessment Scale of Adaptation Difficulty for the Elderly (ASADE) and Geriatric Depression Scale Short Form (GDS-S). Progressive muscle relaxation will be performed for a total of 8 weeks, 3 days a week, for 30 minutes.

Eligibility Criteria:
Inclusion Criteria:

* 65 years and above,
* Do not have a diagnosis of dementia and psychiatric disease by the doctor and have a mini-mental test score of 23 and above,
* Being independent in practicing daily living activities
* There is no problem with communication

Exclusion Criteria:

* Under the age of 65
* Being addicted in daily life activities
* Being diagnosed with dementia and psychiatric illness
* Mini-mental test score below 23
An Intervention Study on the Effect of Brazilian Spinach Supplementation on Health Outcomes Among Type 2 Diabetes Patients in Hospital Universiti Sains Malaysia

The purpose of this study is to determine whether Brazilian spinach supplementation effective in improving the nutritional status of Type 2 Diabetes Mellitus patient.

Background: Vegetables are valuable health promotion foods because they contain vital nutrients such as vitamins, minerals, proteins, fibres and bio-functional components but are low in fat, sodium and calories as compared with many other foods. In terms of body fat, increase vegetable intake that consist of dietary fibre can play an important role in the regulation of body weight. Therefore, the supplementation of dietary fibre intake from vegetable may have benefit in reducing the percentages of body fat. Though, the clinical effect in human remains unclear and currently no study conducted in Malaysia regarding the effectiveness of this plant towards blood sugar control. Apart from that, lower intake of vegetable among Malaysian, lower cost vegetable choices and higher availability of Althernanthera Sissoo (Brazilian Spinach) due to easy growth may benefit the diabetes patient. Therefore, the investigators plan to conduct this study to determine the effectiveness of 12-weeks Brazilian Spinach supplementation on health outcomes among patients with type 2 diabetes especially in Kelantan region. The investigators hypothesized that diabetes patients on supplementation of Brazilian Spinach would have significant differ in terms of anthropometry, biochemical, clinical, and dietary intake compared to control group.

Method: A single-center randomized, controlled, and two-arm parallel design clinical trial will be carried out in Malaysia especially in Kelantan region. This study enrols 100 patients from Hospital Universiti Sains Malaysia (HUSM) diagnosed with type 2 diabetes. Diabetic patients who meet eligibility criteria will be randomly allocated to two groups, which are Brazilian Spinach treatment group and control group. Both groups will be compared on the primary and secondary outcomes at baseline, 3, 6, and 12 weeks.

Discussion: The study will provide insights into the potential beneficial effect of Brazilian Spinach in type 2 diabetic patients. In addition, the therapeutic effect of Brazilian Spinach towards type 2 diabetes will reflect as a change of metabolite profile in serum.

Eligibility Criteria:
Inclusion Criteria:

* Age between 30-65 years old
* Have confirmed diagnosed with type 2 diabetes mellitus of equal or more than 6 months
* HbA1c levels equal or more than 7% (within the last 3 months of recruitment)
* On at least one oral hypoglycemic agent
* Agree not to take other herbal or nutritional supplements for the duration of study.

Exclusion Criteria:

* Unable to tolerate to fiber especially vegetables
* Type 1 diabetes mellitus
* Pregnant
* Insulin treatment
* Severe diabetic complications including end-stage renal diseases, liver diseases or gastrointestinal diseases
* On coagulant therapy (warfarin)
Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline

This study aimed to evaluate the efficacy of low-dose rosuvastatin (10 mg) in the 4 statin benefit groups requiring high- or moderate-intensity statin therapy according to the 2013 American College of Cardiology/American Heart Association guideline in Korean population.

The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol. Secondary endpoints were percentage reduction in other lipids and achievement of ≥50% reduction in LDL cholesterol. Intention-to-treat analyses were performed.

Eligibility Criteria:
Inclusion Criteria:

1. subjects with prior history of clinical ASCVD
2. subjects with primary elevation of LDL cholesterol ≥190 mg/dL
3. subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL
4. subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and with estimated 10-year ASCVD risk ≥7.5%.

Exclusion Criteria:

1. history of significant statin-induced rhabdomyolysis or myopathy
2. history of a significant hypersensitivity reaction to rosuvastatin
3. uncontrolled diabetes mellitus (HbA1c \>9%)
4. uncontrolled hypertension (systolic blood pressure \>190 mmHg or diastolic blood pressure \>100 mmHg)
5. current active liver disease (alanine aminotransferase and/or aspartate aminotransferase \>2 times the upper limit of normal)
6. chronic kidney disease (serum creatinine clearance \<30 ml/min)
7. creatine kinase levels \>3 times the upper limit of normal
8. use of prohibited concomitant therapies
9. history of malignancy within the last 5 years
10. women who were pregnant, breast-feeding or of childbearing potential without contraception
11. subjects who would take any medication for purposes other than this trial within 30 days after taking this study's medication.
Surviving Pneumonia

The study aims to explore risk factors for poor prognosis among patients admitted with community-acquired pneumonia (CAP). During a 5-year study period, all patients (aged ≥ 18 years) admitted with CAP at North Zealand Hospital will be invited for inclusion. Questionnaires, anthropometric measures, laboratory tests, and biomaterials will be collected at admission, daily during admission, at discharge and at follow-up. The main clinical outcomes of the study consist of deaths and development of diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Infiltrate on chest radiograph plus one or more of the following:

  * Fever (temperature, ≥38.0°C)
  * Hypothermia (\<35.0°C),
  * New cough with or without sputum production
  * Pleuritic chest pain
  * Dyspnea
  * Altered breath sounds on auscultation.

Exclusion Criteria:

* Patients unable to give informed consent
* Patients unwilling to give informed consent
Amniotic Biomarkers for the Prediction of Postpartum Renal Function.

The discovery of antenatal bilateral renal anomaly poses an essential question: can we predict postnatal renal function? Ultrasound is insufficiently precise to predict postnatal renal function evolution.

The objective of this study is to estimate the specificity and sensitivity of amniotic fluid biomarkers to predict postnatal renal function in fetuses with bilateral developmental nephropathies.

Both fetuses with bilateral renal anomalies and control (healthy) fetuses will be included.

For this study amniotic fluid will only be collected according to routine clinical practice and only excess amniotic fluid sample will be used for the study.

The potentially identified biomarkers will not change routine management of the pregnancies in the study.


Eligibility Criteria:
INCLUSION CRITERIA:

All fetuses with a bilateral abnormal renal development (structure modification of the parenchyma with or without urinary tract abnormalities associated)

The following sonographic criteria are used:

* Fetal kidney size \<2.5ep or \<2 standard deviation (SD) defining renal hypoplasia or renal size\> 97.5ep or\> 2 SD defining nephromegaly
* And / or hyperechogenicity (more echogenic than the liver kidney)
* And / or cysts
* And / or abnormal cortico-medullary differentiation (decrease or lack thereof)
* And / or bilateral cortical thinning
* And / or the possibility of an initial unilateral renal disease in the case of a pathology on which kidney damage is usually to become bilateral during evolution

EXCLUSION CRITERIA:

* Foetuses with severe malformations that can change the amniotic or urine proteome: complex heart disease, digestive stenosis, fetal immobility.
* Fetus whose mother has chronic infectious diseases (HIV, hepatitis B and C) or acute infectious diseases such chorioamnionitis.
* Parental Refusal.